BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1879298)

  • 1. [Inhibitory effect of monoclonal antibody PD4 on Ha-ras transformed cells Rat3-3].
    Yin WN
    Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):82-6. PubMed ID: 1879298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antisense c-Ha-ras oligodeoxynucleotides inhibit the proliferation of the gastrocarcinoma-DNA-transformed rat 3-3 cells and reduce the p21 expression of the cells.
    Xu Y; Deng GR; Liang YY; Li C
    Sci China B; 1991 Jan; 34(1):35-41. PubMed ID: 2015062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR; Wu CJ; Ke Y; Xiong X; Li YJ; Liu JM; Xu Y; Xu W; Li JY; Deng GR
    Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of antisense DNA and its derivative on gastric transformed cell carcinogenicity].
    Yang D; Li T; Xu W
    Zhonghua Wai Ke Za Zhi; 1995 Jan; 33(1):26-8. PubMed ID: 7774440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.
    Hamilton M; Wolfman A
    Oncogene; 1998 Mar; 16(11):1417-28. PubMed ID: 9525741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ; Austin VN; Zimmer SG; Fisher PB
    Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ras-induced neoplastic transformation and sensitivity to tumor necrosis factor.
    Fernandez A; Chen PW; Ananthaswamy HN
    Anticancer Res; 1994; 14(6B):2649-52. PubMed ID: 7872696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras.
    Kawada M; Fukazawa H; Mizuno S; Uehara Y
    Biochem Biophys Res Commun; 1997 Feb; 231(3):735-7. PubMed ID: 9070883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.
    Daaka Y; Wickstrom E
    Oncogene Res; 1990; 5(4):267-75. PubMed ID: 2204019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts.
    Kivinen L; Pitkänen K; Laiho M
    Oncogene; 1993 Oct; 8(10):2703-11. PubMed ID: 8378082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
    Wang XY; Repasky E; Liu HT
    Exp Cell Res; 1999 Jul; 250(1):253-63. PubMed ID: 10388539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming and oncogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines.
    Wang B; Soule HD; Miller FR
    Anticancer Res; 1997; 17(6D):4387-94. PubMed ID: 9494538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene.
    Kaba DS; Pierceall WE; Price JE; Ananthaswamy HN
    Cancer Res; 1990 Jun; 50(11):3159-66. PubMed ID: 2185882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of the neoplastic phenotype of EBV-established B lymphocytes by the human Ha-ras oncogene.
    Nasi S; Sirinian MI; Panetta G; Marchetti A; Jucker R
    Oncogene; 1990 Jan; 5(1):117-22. PubMed ID: 2157177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
    Kuo ML; Chou YW; Chau YP; Huang TS
    Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21ras independent down-regulation of ras-induced increases in natural antibody binding during tumor progression.
    Tough DF; Feng X; Chow DA
    Nat Immun; 1995; 14(1):20-34. PubMed ID: 7599459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.